According to the American Heart Association the number of adults living with heart failure were
increased around 5.7 million during the year 2009-2012 and was increased around 6.5 million in the
year 2011-2014. Currently the number of people with weak heart or with heart failure is projected to
rise around 46% by 2030.
Also, increase in obese population and rise in demand for minimally invasive procedures are the
other factors leading to the growth of drug eluting stents market in developed as well as emerging
economies. According to the National Center for Health Statistics (NCHS), in the U.S. the
prevalence of obese was around 36% in adult’s and17% in youth in the year 2011–2014.
Rise in chronic disease around the globe and increase in geriatric population expected to
support the growth of drug eluting stents market over the forecast period
Asthma is one of the major chronic disease which in turn can cause to heart failed thus this
demands in the growth of drug eluting stents market. According to the World Health Organization
(WHO) around 235 million people are suffering currently from asthma, it was estimated around
383,000 deaths occurred due to asthma in 2015 and the strong risk factor for asthma are inhaled
substances and particles that causes allergic reaction which are exposed in environment. The
fundamental causes of asthma can be tobacco smoke, chemical irritants at the workplace and air
pollution.
For More Information @ https://www.coherentmarketinsights.com/market-insight/drug-
eluting-stents-market-566
As per the National Institute on Aging the world’s geriatric population in 2015 was around 8.5%
and it may rise around 17% by 2050. Whereas according to the United States Census Bureau in the
U.S around 44.7 million older population was estimate in 2013 and it may rise around 98.2 million
by 2060. This growth of geriatric population may contradict to various diseases such as coronary
diseases, and hence will rise the demand for the growth of drug eluting stents market in the future
near.
The major key players of drug eluting stents market are Boston Scientific Corporation, Medtronic,
Inc., Abbott Laboratories, Biosensors International Group, Biotronik, Lepu Medical Technology,
Terumo Medical Corporation, Cook Medical, Shandong JW Medical Systems, Stentys, Abbott
Vascular Inc., AlviMedica Medical Technologies Inc., Amaranth Medical, Inc., HangZhou HuaAn
Biotechnology Co.,Ltd, XTENT, Inc., CARDIONOVUM GmbH, Cordis Corporation KYOTO
MEDICAL PLANNING Co., Ltd.
Market Taxonomy
This report segments the global drug eluting stents market on the basis of application type, product
type and geography. On the basis of product type, the market is categorized into polymer-based
coatings and polymer free coatings. Among these, the polymer-based coating segment dominate the
drug eluting stents market throughout the forecast period. On the basis of application type the
market is segmented into coronary artery diseases and peripheral artery diseases. Among these
coronary artery diseases type the holds the largest market share throughout the forecast period. On
the basis of geography, the market is divided into North America, Latin America, Europe, Asia
Pacific, Middle East, and Africa. Among all regions, North America contributes major market share
supported by increased incidence rate of cardiovascular disease and growing inclination of the
populace towards minimally invasive procedures.
Detailed Segmentation: